Polyrizon Signs Agreements With Two Additional U.S. Clinical Sites For Nasarix PL-14 Clinical Study

Polyrizon

Polyrizon

PLRZ

0.00

The study, titled "Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis," is designed as a multi-center trial in the United States, with up to five clinical sites expected to participate.

The NASARIX™ investigational product is an intranasal hydrogel formulation intended to create a protective physical barrier in the nasal cavity to block airborne allergens at the point of entry, potentially offering a non-pharmacological approach to allergy prevention.

The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting the Company's broader regulatory strategy.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.